L-arginine (L-Arg) rapidly stimulates GH and insulin release in vivo. It has been hypothesized that L-Arg stimulates GH release by lowering hypothalamic somatostatin (SST) tone. L-Arg may also act directly at the pituitary to stimulate GH release. Moreover, L-Arg has a direct stimulatory effect on ␤-cells, which is thought to be blunted by the release of SST from pancreatic ␦-cells. To confirm the role of endogenous SST on L-Arg-induced GH and insulin release, wild-type (WT) and SST-knockout (SST-KO) mice were injected with L-Arg (ip; 0.8 g/kg), and pre-/post-injection GH, insulin, and glucose levels were measured. In WT mice, L-Arg evoked a 6-fold increase in circulating GH. However, there was only a modest increase in GH levels in WT pituitary cell cultures treated with L-Arg. In contrast, L-Arg failed to increase GH in SST-KO beyond their already elevated levels. These results further support the hypothesis that the primary mechanism by which L-Arg acutely increases GH in vivo is by lowering hypothalamic SST input to the pituitary and not via direct pituitary effects. Additionally, L-Arg induced a clear first-phase insulin secretion in WT mice, but not in SST-KO. However, SST-KO, but not WT mice, displayed a robust and sustained second-phase insulin release. These results further support a role for endogenous SST in regulating L-Arg-mediated insulin release. (Endocrinology 154: 2393-2398, 2013) I t is well documented that injection of the amino acid, L-arginine (L-Arg), rapidly increases circulating GH levels in a variety of species (1-6). This stimulatory action of L-Arg is thought to be primarily mediated by suppressing hypothalamic somatostatin (SST) input to the pituitary somatotropes (1, 7). However, there is also evidence that L-Arg can act directly at the pituitary level to stimulate GH synthesis/release (8 -10). In addition to the stimulatory actions of L-Arg on GH release, L-Arg has also been shown to directly stimulate insulin release from pancreatic ␤-cells. However, in this context, L-Arg also increases SST release from pancreatic ␦-cells, which in turn is thought to suppress the rise in insulin (11-15).
I
t is well documented that injection of the amino acid, L-arginine (L-Arg), rapidly increases circulating GH levels in a variety of species (1) (2) (3) (4) (5) (6) . This stimulatory action of L-Arg is thought to be primarily mediated by suppressing hypothalamic somatostatin (SST) input to the pituitary somatotropes (1, 7) . However, there is also evidence that L-Arg can act directly at the pituitary level to stimulate GH synthesis/release (8 -10) . In addition to the stimulatory actions of L-Arg on GH release, L-Arg has also been shown to directly stimulate insulin release from pancreatic ␤-cells. However, in this context, L-Arg also increases SST release from pancreatic ␦-cells, which in turn is thought to suppress the rise in insulin (11) (12) (13) (14) (15) .
In order to confirm the role of endogenous SST in regulating the stimulatory actions of L-Arg on GH and insulin release in vivo, the current study examined the acute effects of L-Arg on circulating GH and insulin levels in male and female SST-knockout (SST-KO) mice and their wildtype (WT) littermate controls.
Materials and Methods

Animals
Male/female SST-KO and their WT littermate controls were bred in house and maintained on a C57Bl/6J background. The SST-KO strain was originally developed and validated by Zeyda et al. (16) . WT C57Bl/6J mice, (Charles River, Barcelona, Spain), were bred in house and used to prepare primary pituitary cultures to test the direct effects of L-Arg, as described below. All mice were maintained under standard conditions of light (12-h light/ 12-h dark cycle) and temperature (22-24°C) , with free access to tap water and food (SAFE-diets, Barcelona, Spain). All experimental procedures were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Cordoba. Mice were handled daily at least 1 week before any experimental procedure to acclimate them to personnel and handling procedures.
Primary mouse pituitary cell cultures
Primary cultures were prepared from 12-to 13 week-old male and female WT-mice as previously reported (17) . Cells were plated in 48 wells/plate (30 000 cells per well) and incubated in 95% O 2 :5% CO 2 at 37°C for 24 hours in serum containing media [DMEM containing glucose [1 g/liter], 10% fetal bovine serum, 0.15% BSA, 6 mM HEPES, 2 mM L-glutamine, 1% penicillin/streptomycin [Sigma-Aldrich, St. Louis, Missouri]. Then, cells were washed in serum-free media and preincubated for 1 hour. Media were removed and replaced with medium with or without L-Arg (100 M, Sigma-Aldrich). After 1 or 24 hours, medium was removed, centrifuged to discard any detached cells, and then stored at Ϫ20°C for subsequent GH analysis.
L-arginine stimulation tests
Ad libitum fed male/female SST-KO and WT (7 mo-old), were treated with L-Arg [0.8 g/kg, ip, PBS pH 7.4; dose chosen according to previous studies (18) ]. A blood sample was collected from tail vein nicks just before L-Arg injection (t0) and 30 and 60 minutes after injection, for determination of circulating GH levels. One month later, the mice were fasted overnight (16 h ) and again treated with L-Arg, and blood was collected at t0, 30, and 60 minutes postinjection for insulin and glucose determinations. Based on the differences observed in L-Arg-induced insulin secretion between SST-KO and WT at 30 and 60 minutes postinjection, a separate set of male mice (4 mo of age), was fasted overnight and treated with L-Arg, and blood was collected at 0, 2, 5, 15, 30, and 60 minutes postinjection for insulin/glucose determinations to analyze first-phase insulin release. In all experiments, an anesthetic cream (Emla, 2.5% lidocaine: 2.5% prilocaine) was applied 10 minutes before blood collection. Blood was mixed with 1 L 0.32 M K 3 EDTA immediately after collection, centrifuged and plasma stored at Ϫ20°C for subsequent analysis of GH or insulin by ELISA.
Glucose, GH, and insulin measurement
Glucose levels were determined from fresh tail-vein blood samples using the Glucocard-glucometer (Arkray; Amstelveen, The Netherlands). Hormones were assessed using commercial ELISA kits for mouse GH and insulin (Millipore; Madrid, Spain).
Statistical analysis
Student's t tests were used to evaluate the impact of lack of SST on basal GH, glucose (fed/fasted) and insulin within gender, the area under the curve of the glucose response, and to compare the in vitro GH response to L-Arg treatment in WT primary pituitary cultures. One-way ANOVA, followed by NewmanKeuls post hoc test, was used to evaluate the time-dependent impact of L-Arg on GH/insulin/glucose levels. Two-way ANOVA, followed by Bonferroni post hoc test for multiple comparisons, was used to evaluate the impact of lack of SST and L-Arg treatment on GH/insulin/glucose levels.
Results
Male and female SST-KO mice have elevated GH levels, compared with WT controls (Table 1 ). In WT male and female mice, acute injection of L-Arg resulted in an increase in GH levels that reached 6 times the baseline values at 60 minutes after injection ( Figure 1A ). However, L-Arg failed to further augment circulating GH levels in SST-KO mice.
In order to determine whether the L-Arg-induced GH release, observed in WT-mice, is in part due to a direct effect on the pituitary, primary pituitary cultures from WT male and female mice were treated with L-Arg (100 M) or vehicle for 1 or 24 hours. L-Arg stimulated GH secretion in primary pituitary cultures from male (145% of vehicletreated cultures) but failed to modify GH secretion in cultures prepared from female mice ( Figure 1B) .
Under fasted conditions, 4-month-old SST-KO mice were euglycemic, although their insulin levels were greater than in WT controls (Table 1 ). In these same WT mice, L-Arg evoked a rapid rise in insulin, which fell to baseline at 30 minutes postinjection (Figure 2A ). In contrast, a clear first-phase insulin release (0 -5 min) was not observed in SST-KO mice ( Figure 2A) . Interestingly, L-Arg did evoke a significant rise in insulin 15 minutes after injection, which peaked at 30 minutes and declined by 60 minutes, but remained elevated above preinjection values. Despite the L-Arg-induced rise in insulin, glucose levels were also increased after L-Arg injection (5-15 min, Figure 2B ), and this increase was more pronounced in SST-KO mice (area under the curve, 0 -15 min), but returned to control levels by 60 minutes. Consistent with these observations, in an older group of mice (8 mo of age), L-Arg stimulated insulin levels 30 minutes postinjection (earliest time point examined) in SST-KO mice but not WT controls ( Figure 2C ). In contrast to the younger mice, the L-Arg-induced rise in insulin in 7 month-old SST-KO mice was associated with hypoglycemia at 30 and 60 minutes postinjection ( Figure 2D ).
Discussion
Role of endogenous SST in basal and L-Argstimulated GH release L-Arg stimulates GH release in humans, pigs, dogs, rats (1-6), and in mice ( Figure 1A) . However, limited studies have been conducted regarding the mechanism by which L-Arg mediates this effect. Earlier work, in humans, demonstrated that L-Arg could potentiate GH-releasing hormone-induced GH secretion (1, 7) but fails to stimulate GH after pretreatment with exogenous SST analogs (7) . In addition, L-Arg was shown to be an effective stimulator of GH release in pigs, whereas this effect was abolished after hypothalamic-pituitary stalk transection (2, 6). These findings led to the conclusion that the primary mechanism by which L-Arg stimulates GH release is through reducing endogenous hypothalamic SST tone on the pituitary. Therefore, L-Arg alone, or in combination with GHRH, has been routinely used as a diagnostic tool to assess the capacity of the pituitary somatotrope to release GH (for review see Ref. 19 ). The GH-releasing effect of L-Arg was later shown to require GHRH, based on studies showing the GH response to L-Arg was severely blunted in humans pretreated with GHRH antagonists (20 -22) . This finding could be interpreted to mean L-Arg may also stimulate hypothalamic GHRH output, perhaps directly or indirectly, by removing SST inhibition of GHRH-producing neurons (23, 24) . However, the fact that high-dose GHRH effects are enhanced in combination with L-Arg (19) and that SST directly blocks GHRH-stimulated GH release in vitro (25) indicates that L-Arg could rapidly reduce hypothalamic SST tone, allowing for the unimpeded stimulatory actions of endogenous GHRH on GH release.
In order to confirm the role of endogenous SST in mediating the in vivo actions of L-Arg, circulating GH levels were compared in WT and SST-KO mice under basal conditions and after L-Arg challenge. In both male/female WT mice, but not SST-KO mice, a bolus injection of L-Arg dramatically increased circulating GH levels. A direct pituitary effect of L-Arg on in vivo GH release in WT mice is unlikely, based on the modest increase in GH levels observed in primary pituitary cell cultures treated with L-Arg. In line with this, it has been previously reported in a different strain of SST-KO mice (26) that pituitary GH content is reduced and, therefore, it is possible that the pituitary somatotrope of SST-KO mice may not have sufficient GH stores to respond to secretagogue challenge. However, this possibility is lessened by the fact that pulse release is maintained in SST-KO mice (27) and the fact that primary pituitary cell cultures from SST-KO mice respond normally to GHRH challenge (Supplemental Figure 1 published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). Therefore, our current observation, together with previous studies (1, 2, 6, 7), supports the hypothesis that the primary mechanism by which L-Arg acutely increases GH in vivo is by lowering endogenous hypothalamic SST input to the pituitary and not via direct pituitary effects.
Role of endogenous SST in basal and L-Argstimulated insulin release
The postprandial rise in circulating glucose stimulates pancreatic ␤-cells to release insulin and blocks the ability of ␣-cells to release glucagon. Insulin, in turn, is thought to stimulate ␦-cells to release SST, which suppresses both insulin/glucagon release. However, recent data indicate that factors other than insulin may be involved in the glucose-induced rise in SST (28) . Nevertheless, the critical role that SST plays in the paracrine regulation of islet function is supported by studies showing enhanced glucosestimulated insulin secretion (GSIS) in islets from SST-KO mice (13) . Enhanced GSIS is also observed in vivo in mice lacking SST or SST receptors (29 -31) . However, the increase in GSIS in SST/SST receptor-modified mice is ageand sex dependent and is not always associated with an increase in basal insulin levels. In the current report, we did observe a modest but significant increase in fasted insulin levels in male SST-KO, whereas no change in glucose levels was observed (similar to a previous report) (32) . This may be due to the fact that SST-KO mice display enhanced glucagon release (13) , which might counteract peripheral insulin actions. However, we cannot discount the possibility that the elevated GH, ghrelin, and glucocorticoids observed in SST-KO mice (17, 33) may play a role in glucose homeostasis. L-Arg, like glucose, is a well-known direct stimulator of insulin release, an effect that could be mediated through activation of the GPRC6A receptor, although this remains controversial (34, 35) . L-Arg also rapidly stimulates the release of glucagon and SST (13, 14) . In the current report, we show that the insulin response to L-Arg is dramatically altered in SST-KO. Specifically, they lack the first-phase insulin release observed in WT mice. Given that L-Arg has been shown to act directly on ␤-cells to stimulate insulin release, these data suggest that the SST-KO environment leads to ␤-cell dysfunction. One factor that may contribute to this dysfunction in SST-KO mice is elevated ghrelin (32) , in which ghrelin has been shown to attenuate the glucose-mediated rise in intracellular [Ca 2ϩ ] in ␤-cells and to reduce in vivo/in vitro insulin release (36 -38) . Despite the lack of first-phase insulin release, second-phase insulin release was dramatically enhanced in SST-KO. It is unlikely that this effect is directly due to L-Arg-stimulated insulin release, because L-Arg would be rapidly cleared from the system after ip injection. However, one possible secondary effector could be glucagon, because SST-KO has been shown to have enhanced L-Arg-induced glucagon release (13) , and glucagon is known to directly stimulate insulin secretion (39) . Although the importance of locally produced SST in regulating islet homeostasis is clear, we cannot rule out the possibility that loss of hypothalamic SST also impacts islet homeostasis. This possibility is supported by early studies showing that central infusion of SST suppresses insulin, leading to hyperglycemia, and ventral medial hypothalamic lesion results in hyperinsulinemia (40) .
Despite the L-Arg-induced rise in insulin, L-Arg also induced an acute rise in glucose levels, an effect that was more pronounced in SST-KO. This differential response may also be due to enhanced glucagon release (13, 14, 41) . It should be noted that in the younger SST-KO mice (4 mo of age) glucose remained elevated 30 minutes after L-Arg injection, whereas in 8 month-old SST-KO mice, mild hypoglycemia was observed at 30 and 60 minutes after L-Arg injection, consistent with the elevated insulin levels observed in these mice. These differences might be simply due to the age of the mice. They also could be due to experimental processes, in which older mice were only briefly restrained at each time point (0, 30, and 60 min) for blood collection, whereas younger mice were restrained from 0 -15 minutes after L-Arg injection, in order to obtain more frequent blood samples, and prolonged restraint stress has been shown to increase glucose levels in rodents (42) .
Taken together, this work demonstrates the critical role of endogenous SST in mediating the effects of L-Arg on GH and insulin secretion in vivo.
